Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bigger And Smaller? Pfizer Pursues AstraZeneca But Hasn’t Given Up On A Split

Executive Summary

A Pfizer break up is still an option even if the company completes a mega-merger with AstraZeneca, CEO Ian Read said May 5. The company’s first quarter sales and earnings results highlighted how important completing a transaction could be for the company, with sales down 9% and earnings down 15%.


Related Content

Pfizer's Practical Predator: CEO Ian Read
Deal Watch: AstraZeneca/Almirall And Pfizer/Baxter Vaccines Deal Change Math On Future Pfizer/AstraZeneca Bid
Vaccines Chess Game Continues With Baxter Sale To Pfizer
Pfizer Buys InnoPharma As It Buffs Up Established Pharma Unit
AstraZeneca Rejects Pfizer “Final” Offer; Doubts Rise Over Eventual Deal
Deal Watch: Lundbeck Acquires Chelsea As Industry Awaits Possible AstraZeneca, Allergan Buyouts
Pfizer’s Latest Palbociclib Data Could Mean Slimmer Lead Over CDK4/6 Rivals
A Goliath Grows: Pfizer Buys Wyeth For $68 Billion


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts